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Abstract—Unlike natural images, medical images often have
intrinsic characteristics that can be leveraged for neural network
learning. For example, images that belong to different stages
of a disease may continuously follow a certain progression
pattern. In this paper, we propose a novel method that leverages
disease progression learning for medical image recognition. In
our method, sequences of images ordered by disease stages are
learned by a neural network that consists of a shared vision
model for feature extraction and a long short-term memory
network for the learning of stage sequences. Auxiliary vision
outputs are also included to capture stage features that tend to
be discrete along the disease progression. Our proposed method
is evaluated on a public diabetic retinopathy dataset, and achieves
about 3.3% improvement in disease staging accuracy, compared
to the baseline method that does not use disease progression
learning.
Index Terms—disease progression, medical image, deep learn-
ing
I. INTRODUCTION
Deep learning has been widely applied to medical image
recognition since its great success in natural image recognition,
and has achieved state-of-the-art performance in various areas
such as anatomical structure identification, lesion detection
and classification [1], [2]. Unlike general object classification,
medical images often have intrinsic characteristics that can be
exploited to facilitate neural network learning for improved
results. For example, medical recognition tasks on images
acquired from computed tomography (CT) or magnetic res-
onance imaging (MRI) generally favor a 3D convolutional
neural network (CNN) over a 2D CNN, due to the additional
spatial information in three dimensions [3], [4]. Another
example of neural networks that exploit medical intrinsic
information is the BrainNetCNN, where special edge-to-edge,
edge-to-node and node-to-graph convolutional filters are de-
signed to leverage topological locality of brain networks for
the prediction of neurodevelopmental outcomes [5].
In this paper, we propose a novel method that leverages
disease progression learning for medical image recognition.
Concretely, given any medical recognition problem that is
associated with a disease progression, we use long short-
term memory (LSTM) to model the disease progression,
for example, to predict survival time based on brain tumor
images (e.g. short-term survival, medium-term survival and
long-term survival) [6], or a disease staging problem. As
illustrated in Figure 1(a, b, c), the disease staging problem
commonly exists across multiple modalities, including but
not limited to classifying breast histopathological images
into normal, benign, in-situ or invasive [7]; MRI images of
white matter into mild, moderate or severe based on age-
related changes [8]; and retinal fundus images into no-diabetic-
retinopathy (NDR), simple-diabetic-retinopathy (SDR), pre-
proliferative-diabetic-retinopathy (PPDR) or proliferative-
diabetic-retinopathy (PDR) [9]. Rather than considering each
different stage as an independent class as done in most previ-
ous research, we hypothesize that there is a stage difference
memory driven by the disease progression that should also be
represented in the neural network. By leveraging this memory
information from the stage sequence, more robust and optimal
results could be possible.
LSTM is a widely-used network that is powerful for se-
quential data learning, as it has memory units that efficiently
remember previous steps [10]. There are previous publications
using LSTM for medical data, but mostly based on diagnostic
text reports [11], 3D image stacks [12], [13], or clinical
measurements/admissions [14]–[16], among which, some also
use the concept of disease progression modeling [15], [16].
However, all previous work either do not clearly define stage
classes for a disease progression, or still consider each stage
as an independent class and the sequence learning only occurs
within each individual stage class. I.e., there is no explicit
learning of the stage sequence itself, other than learning of
temporal sequence (e.g. a series of clinical events), or spatial
sequence (e.g. 3D MRI/CT images).
To the best of our knowledge, we are the first to use
LSTM for the learning of stage sequence along the disease
progression for medical image recognition, with each stage
represented by feature vectors that are extracted from a well-
established vision model (e.g. GoogleNet or ResNet). Auxil-
iary outputs from the vision model are also adopted in order
to capture stage features that may not be continuous along
the disease progression. Our proposed method is evaluated on
a diabetic retinopathy dataset, where it shows a performance
increase of around 3.3% in disease staging accuracy, compared
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Fig. 1. Examples of disease progression with different stages: (a) Breast cancer with five stages: normal, benign proliferation, atypical hyperplasia, in-situ and
invasive [7]; (b) Aging related changes in white matter with three severity grades: mild, moderate and severe [8]; (c) Diabetic retinopathy with four stages:
no-diabetic-retinopathy (NDR), simple-diabetic-retinopathy (SDR), pre-proliferative-diabetic-retinopathy (PPDR) and proliferative-diabetic-retinopathy (PDR)
[9]; (d) Cyclic form of the stage sequence.
to the baseline method that is similar but without disease
progression learning.
II. METHODS
A. Disease progression learning
Given a disease progression with K sequential stages
S = {Sk, k = 0, 1, ...,K − 1}, with Sk > Sk−1 for each
k ∈ (0,K − 1], where the greater-than sign indicates a disease
progression, meaning stage Sk is a subsequent stage of Sk−1,
e.g. {NDR, SDR, PPDR, PDR} for diabetic retinopathy and
{normal, benign, in-situ, malignant} for epithelial cancers, we
want the neural network to learn disease stage progression by
presenting the network with a sequence of images ordered
by disease stage as the input x = [IS0 , IS1 , ..., ISK−1 ],
where ISk is a randomly selected image that belongs to
stage Sk, and the corresponding output is simply the ordered
full sequence of all disease stages: y = [S0, S1, ..., SK−1].
However, with the above design, all the input samples would
share the same output y that is fixed by the disease stage
progression, making the network training meaningless. To
overcome this problem, we artificially define S0 > SK−1
to make the stage sequence cyclic (Figure 1(d)), so that
multiple ordered full sequences of all disease stages can be
generated. Therefore, [S1, S2, ..., SK−1, S0], for example, is
also considered as a valid ordered full sequence containing all
stages for a certain disease. As a result, the notation of stage
sequence for a training sample can be updated more formally
by the introduction of a modulo operation as the following:
(x,y) = ( [ISi+0 (mod K) , ISi+1 (mod K) , ..., ISi+K−1 (mod K) ],
[Si+0 (mod K), Si+1 (mod K), ..., Si+K−1 (mod K)] )
(1)
where i ∈ [0,K − 1] can be considered as the step shift
size, indicating the starting stage of a sequence, and K is
the total number of disease stages. For simplicity of notation
and explanation, we use the stage sequence of i = 0 as an
illustration in the following.
As shown in Figure 2, the proposed method contains a
vision model (e.g. GoogleNet or ResNet) for the feature
extraction, followed by a LSTM model for the purpose of dis-
ease progression learning. The vision model extracts a feature
vector zSk ∈ RC from its corresponding input image ISk for
each disease stage Sk, and then the concatenated feature vector
sequence of all stages z = [zS0 , zS1 , ...,zSK−1 ] ∈ RK×C is
given as the input to LSTM. The LSTM maintains a hidden
state hSk ∈ RG and a cell state cSk ∈ RG, which are updated
at each stage step k ∈ (0,K − 1]:
hSk , cSk = LSTM(zSk ,hSk−1 , cSk−1) (2)
The hidden state sequence of all stages h =
[hS0 ,hS1 , ...,hSK−1 ] ∈ RK×G is collected from the
multi-output LSTM to learn a softmax classifier F , which
finally outputs the hypotheses yˆ of the true stage labels y:
yˆ = F(h;θ) (3)
where θ is the parameter for classifier F . Note that yˆ =
[yˆS0 , yˆS1 , ..., yˆSK−1 ] ∈ RK×K , where each sequence element
represents a probability distribution over K stage labels for its
corresponding stage. Also, it is worth noting that although for
the simplicity of notation, we denote both h and yˆ as vector
sequences of all stages, the softmax classifier F is actually
applied to each individual hidden state hSk independently to
obtain its corresponding hypothesis yˆSk .
Fig. 2. The architecture of our proposed network.
Our loss function is a weighted summation of cross entropy
losses at all stages:
Loss(yˆ,y) =
K−1∑
k=0
αk · l(yˆSk , Sk) (4)
where αk is the loss weight for each stage output and
l(yˆSk , Sk) =
K−1∑
j=0
− log yˆSkj · δ(Sk = Sj) (5)
is the cross entropy loss function, with yˆSkj denoting for the
probability value of image ISk belonging to the stage label
Sj .
B. Auxiliary vision outputs
In addition to disease progression learning, the network
should also be able to capture stage-wise discriminative fea-
tures that tend to be discrete among different stages along the
disease progression, e.g. features that only appear in a certain
disease stage. Given this thought, we also design auxiliary
outputs directly from the vision model extracted features z
with another softmax classifier Fv on top of the vision model:
yˆv = Fv(z;θv) (6)
To distinguish the two classifiers on top of LSTM model (Fl)
and vision model (Fv), Equation (3) is updated as:
yˆl = Fl(h;θl) (7)
Similarly to LSTM outputs, the loss for auxiliary vision
outputs is also defined as the weighted summation of cross
entropy losses at all disease stages. Taking both losses into
account, the final loss function for our proposed network is:
Loss(yˆl, yˆv,y) =
K−1∑
k=0
(
αk ·l(yˆSkl , Sk)+βk ·l(yˆSkv , Sk)
)
(8)
The loss weights αk and βk for each stage should be chosen
depending on each individual disease progression. A heuristic
choice is that more weight should be given to βk if the stage
features tend to be more discrete.
C. Non-regression disease stage sequence
In the context of disease progression learning (Section
II-A), we artificially define S0 > SK−1 to make the stage
sequence cyclic, so that more variations of stage sequences
can be generated for a particular disease to facilitate the
neural network training. However, it is a bit counter-intuitive
at the first thought to define S0 > SK−1, which violates
the concept of monotonic disease progression. Alternatively,
we could also use other approaches that do not require any
similar assumptions, such as non-regression disease stage
sequence, where the sequence can still start with any arbitrary
disease stages and the disease simply stops progression when
it reaches its final stage. In this way, the order of disease
stages is still maintained without the assumption defined in the
cyclic strategy. For example, [S1, S2, ..., SK−2, SK−1, SK−1]
is also a valid non-regression stage sequence. Therefore, a
training sample of non-regression disease stage sequence can
be formulated as the following:
(x,y) = ( [ISmin(i+0,K−1) , ISmin(i+1,K−1) , ..., ISmin(i+K−1,K−1) ],
[Smin(i+0,K−1), Smin(i+1,K−1), ..., Smin(i+K−1,K−1)] )
(9)
where i ∈ [0,K − 1] is the step shift size, indicating the
starting stage of a sequence, and K is the total number
of disease stages. Although a non-regression disease stage
sequence is more intuitive as compared to a cyclic stage
sequence, we will show in Section III-C that it does not
outperform the cyclic stage sequence.
D. Testing phase
In the testing phase, given an image Itest, an artificial image
sequence is generated by repeating Itest for K iterations, and
then the sequence is fed into the trained network. Due to the
design of our network, we have two options to predict its
stage label based on either LSTM output yˆl or vision output
yˆv (see Figure 2). In both cases, only the first stage output
in the sequence is reported as the final predicted label. Note
that the input image sequence can be started with any arbitrary
stage as we described earlier in Section II-A and Section II-C.
Therefore a faked sequence starting with Itest can still result
in a reasonable prediction of stage label for Itest based on its
corresponding first stage output, although the rest stage outputs
are invalid since there is no disease progression in the input
sequence.
E. Baseline network
The baseline network for this study is the same vision model
followed by the same softmax classifier Fv as used in our
proposed network, except that the input is a single image,
similar to most previous research work on medical image
classification.
For a fair comparison, we also make sure that both networks
are trained on exactly the same amount of augmented data,
which we will describe in detail in Section III-B, to rule out
the possibility that a superior performance could be gained
simply due to larger training samples, given the fact that the
input size of our proposed network is K times bigger than
that of the baseline network.
III. EXPERIMENTS AND RESULTS
A. Dataset
To evaluate our proposed network, we choose to use a
recently published dataset on diabetic retinopathy [9], which
contains fundus photographs of four stages. The dataset has
two sets of class labels based on whether to grade with
wider retinal area: Davis grading of one figure and Davis
grading of concatenated figures, and we use the former in
our experiments. There are in total 9939 images, with 6561 of
NDR, 2113 of SDR, 460 of PPDR and 805 of PDR.
Unlike previous work [9], we address the data imbalance
problem by undersampling by a random selection of 460
images from each stage class for each independent experiment,
and moreover, all the images are resized to 200× 200 instead
of 1272 × 1272 to speed up training, since it is not our
purpose here to compete with the result in [9], but rather to
investigate the advantage of disease progression learning in
stage classification.
Out of the final resulting dataset, 10% of the data is
randomly reserved for testing, and the rest is further split
into two parts: 90% for training and 10% for validation. Data
augmentation is performed on the training set by only using
random rotations from −5◦ to 5◦ without shifts or flips, as all
the images share the same position.
B. Implementation details
We examine two types of vision models in our experiments:
GoogleNet and ResNet-50, both of which were pretrained on
ImageNet. The freeze layer is set to 64 for GoogleNet and
36 for ResNet-50. We use C = 256 for the dimension of
extracted feature vectors, G = 256 for the LSTM model and
α = β = 1 ∈ RK . All models are implemented in Keras with
Theano backend, and trained using stochastic gradient descent,
with the initial learning rate set to 0.001, decay by 1e-6 over
each update, and Nestrov momentum is set to 0.9.
For each independent experiment, we evaluate the proposed
network and baseline network on the same random split of the
dataset. We repeat the above comparison experiment for 20
times, each with a different split. To make sure both networks
are trained on the same amount of augmented data, the same
number of iteration steps per epoch (i.e. 100 steps and 500
steps) is used in the training, until the validation loss does not
drop for ten epochs (patience = 10, with the maximum number
of epochs set to 100). In order to compensate the input size
difference (i.e. one-image input against four-image input), the
batch size for the baseline network training is set to 64 and
decreased to 16 for our proposed network. Note that this is
the only difference in hyper-parameter settings for the training
of the two networks.
C. Results
Table I shows the performance comparison of our pro-
posed method and the baseline method, with both results of
GoogleNet Inception v3 and ResNet-50 as the vision model.
As shown in the table, our proposed method outperforms the
baseline across all experimental settings that are used in this
paper (choices of vision model and training steps per epoch),
and on average, there is about 3.3% accuracy gain (2.4%,
3.6%, 3.4% and 3.6% for each setting respectively). How-
ever, we do not observe a significant performance difference
between vision outputs and LSTM outputs (59.4% vs 59.2%,
63.1% vs 62.9%, 60.7% vs 60.7% and 61.4% vs 61.7%) for
our proposed method, probably due to the joint training of
our model, so that the LSTM backpropagates the gradients to
CNN to force it to learn features that are more stage-relevant,
thus improving the vision outputs.
For both methods, accuracy performance can be improved
with an increased number of training steps per epoch, which
is within our expectation since more steps means more data
augmentation. The best performance in our performed exper-
iments is 63.1% for our proposed method and 59.5% for the
baseline method, both of which are using GoogleNet Inception
v3 pretrained on ImageNet with 500 training steps per epoch,
and the confusion matrices are given in Figure 3. It is also
TABLE I
PERFORMANCE COMPARISONS OF THE BASELINE METHOD AND OUR PROPOSED METHOD TRAINED ON CYCLIC STAGE SEQUENCES (WITH BOTH VISION
OUTPUTS AND LSTM OUTPUTS).
Vision model Steps a Method Accuracy
GoogleNet
Inception v3
100
BASELINE 57.0± 3.2%
OURS(VISION OUTPUT) 59.4± 3.1%
OURS(LSTM OUTPUT) 59.2± 3.3%
500
BASELINE 59.5± 3.3%
OURS(VISION OUTPUT) 63.1± 2.7%
OURS(LSTM OUTPUT) 62.9± 3.0%
ResNet-50
100
BASELINE 57.3± 6.4%
OURS(VISION OUTPUT) 60.7± 5.4%
OURS(LSTM OUTPUT) 60.7± 5.7%
500
BASELINE 58.1± 4.8%
OURS(VISION OUTPUT) 61.4± 3.8%
OURS(LSTM OUTPUT) 61.7± 3.9%
aTraining steps per epoch.
noted that most of the misclassified samples are located in
NDR and SDR, which is reasonable since the two stages are
often quite indistinguishable from a clinical perspective.
We believe that there is still room for performance im-
provement on this particular diabetic retinopathy problem by
doing more data augmentation, using oversampling instead of
undersampling (i.e. to make full use of images in the dataset),
and using the original high resolution images. However, the
Fig. 3. Confusion matrices of the baseline method (left) and our proposed
method (right) using GoogleNet as the vision model with 500 training steps
per epoch.
purpose of this paper is to present and validate the idea of
disease progression learning, and we leave the optimization
for our next study.
To further test the alternative design of disease progression
learning using non-regression stage sequences, we perform
the comparison experiments using the same above settings,
except that the model is trained on non-regression stage
sequences (described in Section II-C), instead of cyclic stage
sequences (described in Section II-A). As shown in Table II,
the non-regression stage sequence fails to outperform cyclic
stage sequence in all experiment settings, and in some case
(GoogleNet and 100 training steps per epoch), it is even worse
compared to the baseline method. The best result achieved by
non-regression stage sequence is 61.8%, which is still worse
than that of cyclic sequence 63.1%.
Based on the above results, we argue that despite being
counter-intuitive at first thought, the cyclic strategy is merely
to facilitate the training, which allows for cyclic variations of
the training data that then de-emphasizes the first class as the
first node, etc. This in turn allows the same disease progression
sequence to be used for more training data. Since the change
will be very abrupt from the last node to the first node, the
learning will still retain the last node’s characteristics as being
TABLE II
PERFORMANCE COMPARISONS OF THE BASELINE METHOD AND OUR PROPOSED METHOD TRAINED ON NON-REGRESSION STAGE SEQUENCES (WITH
BOTH VISION OUTPUTS AND LSTM OUTPUTS).
Vision model Steps a Method Accuracy
GoogleNet
Inception v3
100
BASELINE 57.5± 2.9%
OURS(VISION OUTPUT) 56.2± 3.8%
OURS(LSTM OUTPUT) 55.7± 4.4%
500
BASELINE 59.1± 3.5%
OURS(VISION OUTPUT) 61.8± 2.7%
OURS(LSTM OUTPUT) 60.9± 2.5%
ResNet-50
100
BASELINE 56.5± 5.8%
OURS(VISION OUTPUT) 58.1± 5.0%
OURS(LSTM OUTPUT) 59.6± 4.3%
500
BASELINE 58.2± 3.5%
OURS(VISION OUTPUT) 60.5± 2.5%
OURS(LSTM OUTPUT) 60.1± 2.8%
aTraining steps per epoch.
substantially distinct from the first node of the sequence.
IV. CONCLUSION
In this paper, we present a novel method for medical image
recognition by leveraging disease progression learning, where
stage sequences are learned by LSTM after feature extraction
with a shared vision model for the images from each stage.
Compared to the baseline method that is a pure vision model,
our proposed method has an average of 3.3% accuracy increase
based on our performed experiments, when evaluated for the
problem of disease staging on a diabetic retinopathy dataset.
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